INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.	SERIAL NO.
1000.06.	10/082,521
TUMOR CHEMOPOTENTIATION	
FILING 02/22/02	GROUP 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	6,020,363	02/01/00	HIRANO, ET AL	514	15	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	B1							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

		C1	Teicher et al., "Optimal Scheduling of Interleukin-12 and Fractionated Radiation Therapy in the Murine Lewis Lung Carcinoma," Radiation Oncology Investigations, 6:71-80, 1998.
		C2	Kawai et al., "Enhancement of Anticancer Effects of Radiation and Conventional Anticancer Agents by a Quniolinone derivative, Vesnarinone: Studies on Human Gastric Cancer Tissues in Nude Mice, Anticancer Res., 18:405-412, 1998.

EXAMINER Jacqueline Stone DATE CONSIDERED May 03 2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)	Application Number
1000.06.	09/794,417
Applicant(s)	
TUMOR RADIOSENSITIZATION . . .	
Filing Date	**Group Art Unit**
02/27/01	1614

*EXAMINER INITIAL		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	C3	Voest et al., "Inhibition of Angiogenesis In Vivo by Interleukin 12," J. Nat'l Cancer Inst., 87:581-586, 1995.
	C4	Gorski et al., "Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation, Cancer Res., 59:3374-3378, 1999.
	C5	Norioka et al., "Interaction of Interleukin-1 and Interferon-g on Fibroblast Growth Factor-Induced Angiogenesis, Jpn. J. cancer Res., 85:522-529, 1994.
	C6	Mauceri et al., "Combined effects of Angiostatin and Ionizing Radiation in Antitumor Therapy," Nature, 394:287-291, 1998.
	C7	Matsumoto et al. "Synthesis and Biological Evaluation of Cytogenin Derivatives," J. Antibiotics, 54:285-296, 2001.
	C8	Salloum et al., "NM-3, an Isocoumarin, Increases the Antitumor Effect of radiotherapy without Toxicity, Cancer Res., 60:6958-6963, 2000.
	C9	Agata et al., "NM-3, a Novel Angiogenesis Inhibitor, Potentiates Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells, Proceedings of the 2001 AACR-NCI-EORTC International Conference, p67 October 2001.
	C10	Yin et al., "The Novel Isocoumarin 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) Propionic Acid (NM-3) Induces lethality of Human Carcinoma Cells by Generation of Reactive Oxygen Species," Mol. cancer Therapeutics, 1:43-48, 2001.
	C11	Reimer et al., "Antineoplastic Effects of Chemotherapeutic Agents are Potentiated by NM-3, an Inhibitor of Angiogenesis," Cancer Res., 62:789-795, 2002.
	C12	Nakashima, et al., "Inhibition of Angiogenesis by a New Isocoumarin NM-3," J. Antibiotics, 52:426-428, 1999.
	C13	Kumagi, et al., "Antitumor Activity of Cytogenin," J. Antibiotics, 48:175-178, 1995.
	C14	Oikawa, et al., "Effects of Cytogenin, a Novel Microbial Product, on Embryonic and Tumor Cell-Induced Angiogenic Responses In Vivo," Anticancer Res., 17:1881-1886, 1997.

EXAMINER	DATE CONSIDERED
	May 3 2003

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.